ANTARES PHARMA, INC. Inactive Instrument
Antares Pharma, Inc.
Equities
ATRS
US0366421065
Medical Equipment, Supplies & Distribution
Presentation Operator MessageOperator (Operator)Welcome to the Antares Pharma Inc. 2021 Annual...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic products using its drug delivery systems. The Company products include XYOSTED (testosterone enanthate) injection, NOCDURNA (desmopressin acetate), OTREXUP (methotrexate) injection, Epinephrine Injection USP, Sumatriptan Injection USP, Makena Subcutaneous Auto Injector and Teriparatide Injection. Its testosterone enanthate injection product is indicated for testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Its desmopressin acetate is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate.
| 1st Jan change | Capi. | |
|---|---|---|
| -5.01% | 182B | |
| +1.25% | 110B | |
| -3.10% | 68.11B | |
| +2.68% | 50.53B | |
| +9.65% | 44.8B | |
| +2.84% | 40.7B | |
| +21.37% | 32.25B | |
| +4.13% | 26.53B | |
| +15.25% | 25.02B |
